NCT04616560 2026-04-13
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Suspended
Clinical Trials
12 trialsNCT06311214 2026-04-13
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04482309 2026-04-09
DPT02
AstraZeneca
Phase 2 Active not recruiting
NCT05034887 2026-04-08
Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT05408845 2026-04-03
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
Phase 2 Recruiting
NCT05744375 2026-04-02
TRANSCENDER
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT06486883 2026-04-02
PONTIAC
MedSIR
Phase 2 Recruiting
NCT05480384 2026-04-01
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
Phase 2 Active not recruiting
NCT07371585 2026-03-27
TOP-REAL
SOLTI Breast Cancer Research Group
Phase 2 Recruiting
NCT07497386 2026-03-27
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Not yet recruiting
NCT04539938 2026-03-23
HER2CLIMB-04
Seagen Inc.
Phase 2 Completed
NCT04639219 2026-03-23
DPT01
AstraZeneca
Phase 2 Active not recruiting